SitNews - Stories in the News - Ketchikan, Alaska

Trial Drug Said To Offer Pandemic Hope

 

April 09, 2020
Thursday PM


(SitNews) - Scientists around the world, including Canada, are working tirelessly on the development and testing of new treatments and vaccines to help contain the current outbreak of COVID-19.

Among them is University of British Columbia’s Dr. Josef Penninger. He is the senior scientist leading an international research team that has found a trial drug which is said to effectively block the cellular door that the novel coronavirus uses to infect its hosts. The team’s findings hold promise for a treatment capable of stopping early infection of COVID-19. On Wednesday, April 8th, Dr. Penninger held a live Q&A to discuss more about this cutting-edge research and the hope it offers in the global fight against COVID-19.

jpg Trial Drug Said To Offer Pandemic Hope

In cell cultures analyzed in the current study, hrsACE2 inhibited the coronavirus load by a factor of 1,000-5,000.
Credit: IMBA/Tibor Kulcsar

In case you missed Wednesday's webinar, the findings, published this month in Cell, hold promise as a treatment capable of stopping early infection of the novel coronavirus that, as of April 9th, has affected, according to the World Health Organization, more than 1,439,515 people and claimed the lives of 85,711 people worldwide. 427,460 of the wordwide cases are in the United States with 14,696 of those deaths in the U.S., according to the Center for Disease Control.

Penninger's study provides new insights into key aspects of SARS-CoV-2, the virus that causes COVID-19, and its interactions on a cellular level, as well as how the virus can infect blood vessels and kidneys.

“We are hopeful our results have implications for the development of a novel drug for the treatment of this unprecedented pandemic,” says Penninger, professor in UBC’s faculty of medicine, director of the Life Sciences Institute and the Canada 150 Research Chair in Functional Genetics at UBC.

“This work stems from an amazing collaboration among academic researchers and companies, including Dr. Ryan Conder’s gastrointestinal group at STEMCELL Technologies in Vancouver, Nuria Montserrat in Spain, Drs. Haibo Zhang and Art Slutsky from Toronto and especially Ali Mirazimi’s infectious biology team in Sweden, who have been working tirelessly day and night for weeks to better understand the pathology of this disease and to provide breakthrough therapeutic options.”

jpg Dr Josef Penninger.

Dr Josef Penninger.
Photo Credit: By Paul Joseph/UBC

ACE2 - a protein on the surface of the cell membrane - is now at centre-stage in this outbreak as the key receptor for the spike glycoprotein of SARS-CoV-2. In earlier work, Penninger and colleagues at the University of Toronto and the Institute of Molecular Biology in Vienna first identified ACE2, and found that in living organisms, ACE2 is the key receptor for SARS, the viral respiratory illness recognized as a global threat in 2003. His laboratory also went on to link the protein to both cardiovascular disease and lung failure.

While the COVID-19 outbreak continues to spread around the globe, the absence of a clinically proven antiviral therapy or a treatment specifically targeting the critical SARS-CoV-2 receptor ACE2 on a molecular level has meant an empty arsenal for health care providers struggling to treat severe cases of COVID-19.

“Our new study provides very much needed direct evidence that a drug — called APN01 (human recombinant soluble angiotensin-converting enzyme 2 – hrsACE2) — soon to be tested in clinical trials by the European biotech company Apeiron Biologics, is useful as an antiviral therapy for COVID-19,” says Dr. Art Slutsky, a scientist at the Keenan Research Centre for Biomedical Science of St. Michael’s Hospital and professor at the University of Toronto who is a collaborator on the study.

In cell cultures analyzed in the current study, hrsACE2 inhibited the coronavirus load by a factor of 1,000-5,000. In engineered replicas of human blood vessel and kidneys — organoids grown from human stem cells — the researchers demonstrated that the virus can directly infect and duplicate itself in these tissues. This provides important information on the development of the disease and the fact that severe cases of COVID-19 present with multi-organ failure and evidence of cardiovascular damage. Clinical grade hrsACE2 also reduced the SARS-CoV-2 infection in these engineered human tissues.

“Using organoids allows us to test in a very agile way treatments that are already being used for other diseases, or that are close to being validated. In these moments in which time is short, human organoids save the time that we would spend to test a new drug in the human setting,” says Núria Montserrat, ICREA professor at the Institute for Bioengineering of Catalonia in Spain.

“The virus causing COVID-19 is a close sibling to the first SARS virus,” adds Penninger. “Our previous work has helped to rapidly identify ACE2 as the entry gate for SARS-CoV-2, which explains a lot about the disease. Now we know that a soluble form of ACE2 that catches the virus away, could be indeed a very rational therapy that specifically targets the gate the virus must take to infect us. There is hope for this horrible pandemic.”

This research was supported in part by the Canadian federal government through emergency funding focused on accelerating the development, testing, and implementation of measures to deal with the COVID-19 outbreak.

 

On the Web:

Journal Cell: Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2 (pdf)

Edited By Mary Kauffman, SitNews

Source of News:

University of British Columbia
www.ubc.ca

Institute for Bioengineering of Catalonia in Spain
http://www.ibecbarcelona.eu/research-groups/

Keenan Research Centre for Biomedical Science of St. Michael’s Hospital
http://stmichaelshospitalresearch.ca/

Institute of Molecular Biology in Vienna
https://www.imba.oeaw.ac.at

STEMCELL Technologies
http://www.stemcell.com/

Representations of fact and opinions in comments posted are solely those of the individual posters and do not represent the opinions of Sitnews.



Send a letter to the editor@sitnews.us

Contact the Editor

SitNews ©2020
Stories In The News
Ketchikan, Alaska

 Articles & photographs that appear in SitNews are considered protected by copyright and may not be reprinted without written permission from and payment of any required fees to the proper freelance writers and subscription services.

E-mail your news & photos to editor@sitnews.us

Photographers choosing to submit photographs for publication to SitNews are in doing so granting their permission for publication and for archiving. SitNews does not sell photographs. All requests for purchasing a photograph will be emailed to the photographer.